Telehealth Nurse Service

The Patients Pathways Nurse at Emerge Australia focuses on short, 1:1 support. Consultations are conducted with a registered nurse, free of charge, for people who live in Australia.

Book a Telehealth Nurse Consultation

What the Patient Pathways Nurse can offer

The Patient Pathways nurse will aim to provide you with information that may support you to:

work with your healthcare team to build a stepwise symptom management plan
describe your functional impairment and its connection to ME/CFS
pacing support
discuss how you can put your best Disability Support Pension (DSP) and National Disability Insurance Scheme (NDIS) application forward
additional support as discussed with the National Patient Support and Information Service

Prior to your Telehealth Nurse call, you will be asked to provide some information for data analysis to meet our funding obligations.

What you can expect during your initial Patient Pathways nurse consultation

The consultation may cover:

medical history
personal history
relevant information relating to your treatments and quality of life

The call will last 20 to 30 minutes, but can be shorter to work within your energy limits. The Nurse will discuss your medical history and, if appropriate, provide you with resources or advice that allows you to continue your health journey. 

Together we will decide if you may benefit from further consultation. 

The service has received overwhelmingly positive feedback from patients and carers, who report that they feel more empowered during their medical consultations, and have had success in obtaining services that improve their quality of life.

Book a Telehealth Nurse Consultation

Emergency Support

People with and without ME/CFS go through difficult times at one point or another. It's important to not give up hope and seek help when you need support.

If this is an emergency call 000

Immediate help is available through:

Lifeline on 13 11 14
Suicide Call Back Service on 1300 659 467
Kids Help Line on 1800 55 1800

Latest

Research Digest 01/12/22

Welcome to the 90th edition of the Research Digest. This month's edition features ME/CFS studies investigating microclotting and antibody targeting of gut bacteria. Also presented, is the study of serum samples from post-covid syndrome and -/+ME/CFS patients, to further study endothelial dysfunction and the role of angiogenesis in both study groups. And finally, the recent ABC news article featuring Chris Armstrong and Anne Wilson is highlighted.
Change to eligibility for oral COVID-19 treatments

The Pharmaceutical Benefits Advisory Committee recommended changes to the Pharmaceutical Benefits Scheme (PBS) eligibility criteria of oral treatments for COVID-19.
Living with Severe ME/CFS

It is estimated 25% of individuals living with ME/CFS have severe or very severe symptoms. Ricky Buchanan worked with Emerge Australia to create some tips and hacks for those living with severe ME/CFS.
Post-Infection disease: Australia’s 10th National Health Priority Area

Emerge Australia strongly advocates for the Federal Department of Health to make post-infection disease Australia’s 10th National Health Priority Area (NHPA). The number of Australians living with post-infection disease is rapidly increasing, predicted to be over half a million by the end of 2022, due to a new cohort of post-infection disease patients: those with Long COVID.